Adenovirus-mediated interleukin-12 gene therapy for prostate cancer

Yasutomo Nasu, Shin Ebara, Hiromi Kumon

Research output: Contribution to journalReview articlepeer-review

3 Citations (Scopus)


As a human prostate cancer gene therapy trial, we have performed Herpes Simplex Virus-thymidine kinase gene transduction and ganciclovir therapy in locally advanced prostate cancer after radiation therapy(USA) or endocrine therapy(Japan). Safety and clinical efficacy were confirmed. In our current studies, we demonstrated the efficacy and safety of gene therapy approaches using recombinant adenoviral vector that transduce interleukin-12 in an orthotopic mouse model of prostate cancer. These preclinical studies will soon be resulted in the initiation of clinical trials using this approach(USA: FDA approved, Japan: Under IRB review) in advanced prostate cancer patients with or without metastasis after endocrine therapy. In this chapter, preclinical data and clinical protocol are introduced.

Original languageEnglish
Pages (from-to)1181-1191
Number of pages11
JournalNippon rinsho. Japanese journal of clinical medicine
Issue number6
Publication statusPublished - Jun 2004

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Adenovirus-mediated interleukin-12 gene therapy for prostate cancer'. Together they form a unique fingerprint.

Cite this